Results for 'CMO ADC'
Content Type: All
Sorted by: Relevance
Showing 31 to 40 results of 442
News
ADC Bio Extends with Tech. Service Lab
R&D emphasis for additional £125,000 facility.
Product News
Tumor Regression with New Antibody-Drug Conjugate
Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), has announced the first data on its lead ADC, IKS01.
News
Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer
Data demonstrating excellent specificity presented at AACR.
News
Seattle Genetics and Agensys Announce Co-Development of Antibody-Drug Conjugate
Seattle Genetics has exercised an option to co-develop an additional ADC under the companies’ existing ADC collaboration agreement.
News
Mersana Therapeutics Presents Positive Data on Next-Gen Antibody-Drug Conjugate Technology
Conjugation technology advancements further demonstrate stability, activity and selectivity of Mersana’s ADCs.
News
ADC Therapeutics and BZL Biologics Announces Licensing and Collaboration Agreement
Company licenses proprietary antibody from BZL Biologics for prostate cancer.
Article
Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets
Antibody Drug Conjugates (ADCs) combine the cell-targeting specificity of a monoclonal antibody with a potent cytotoxin payload. This article explains how ADCs can be Cancer's magic bullets, but also describes how their manufacture has posed a challenge to the pharmaceutical industry.
News
ADC Therapeutics Appoints CEO
Company announces appointment of Dr. Chris Martin.
News
PolyTherics Announces a Research Collaboration with Spirogen to Develop ADCs
Companies will combine site-specific conjugation with novel potent cytotoxics.
News
Genmab and ADC Therapeutics Enter Co-Development Collaboration
Combines strength of HuMax®-TAC with next generation PBD-based warhead technology.
Advertisement
